Chen, M.; Wang, Z.; Liu, Z.; Liu, N.; Fang, W.; Zhang, H.; Jin, X.; Li, J.; Zhao, W.; Qu, H.;
et al. The Optimal Therapy after Progression on Immune Checkpoint Inhibitors in MSI Metastatic Gastrointestinal Cancer Patients: A Multicenter Retrospective Cohort Study. Cancers 2022, 14, 5158.
https://doi.org/10.3390/cancers14205158
AMA Style
Chen M, Wang Z, Liu Z, Liu N, Fang W, Zhang H, Jin X, Li J, Zhao W, Qu H,
et al. The Optimal Therapy after Progression on Immune Checkpoint Inhibitors in MSI Metastatic Gastrointestinal Cancer Patients: A Multicenter Retrospective Cohort Study. Cancers. 2022; 14(20):5158.
https://doi.org/10.3390/cancers14205158
Chicago/Turabian Style
Chen, Mifen, Zhenghang Wang, Zimin Liu, Ning Liu, Weijia Fang, Hangyu Zhang, Xuan Jin, Jiayi Li, Weifeng Zhao, Huajun Qu,
and et al. 2022. "The Optimal Therapy after Progression on Immune Checkpoint Inhibitors in MSI Metastatic Gastrointestinal Cancer Patients: A Multicenter Retrospective Cohort Study" Cancers 14, no. 20: 5158.
https://doi.org/10.3390/cancers14205158
APA Style
Chen, M., Wang, Z., Liu, Z., Liu, N., Fang, W., Zhang, H., Jin, X., Li, J., Zhao, W., Qu, H., Song, F., Chang, Z., Li, Y., Tang, Y., Xu, C., Zhang, X., Wang, X., Peng, Z., Cai, J.,
... Shen, L.
(2022). The Optimal Therapy after Progression on Immune Checkpoint Inhibitors in MSI Metastatic Gastrointestinal Cancer Patients: A Multicenter Retrospective Cohort Study. Cancers, 14(20), 5158.
https://doi.org/10.3390/cancers14205158
